Domain‐Specific Prediction of Clinical Progression in Parkinson's Disease Using the Mosaic Approach
Brain and Behavior · 2025
DOI: 10.1002/brb3.70289 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brain and Behavior, 2025. Verfasst von Marlene Tahedl und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuroradiology, School of Medicine and Health, Technical University of Munich, Munich, Germany. Hauptthemen laut MEDLINE: Parkinson Disease, Disease Progression, Magnetic Resonance Imaging. Die Arbeit nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Parkinson's Progression Markers Initiative (PPMI).
Abstract (Originalsprache)
Purpose
Due to the highly individualized clinical manifestation of Parkinson's disease (PD), personalized patient care may require domain‐specific assessment of neurological disability. Evidence from magnetic resonance imaging (MRI) studies has proposed that heterogenous clinical manifestation corresponds to heterogeneous cortical disease burden, suggesting customized, high‐resolution assessment of cortical pathology as a candidate biomarker for domain‐specific assessment.
Method
Herein, we investigate the potential of the recently proposed Mosaic Approach (MAP), a normative framework for quantifying individual cortical disease burden with respect to a population‐representative cohort, in predicting domain‐specific clinical progression. Using MRI and clinical data from 135 recently diagnosed PD patients from the Parkinson's Progression Markers Initiative, we first defined an extremity‐specific motor score. We then identified cortical regions corresponding to “extremity functions” and restricted MAP, respectively, and contrasted the explanatory power of the extremity‐specific MAP to unrestricted MAP. As control conditions, domain‐related but less specific general motor function and nondomain‐specific cognitive scores were considered. We also tested the predictive power of the restricted MAP in predicting disease progression over 1 and 3 years using support vector machines. The restricted, extremity‐specific MAP yielded higher explanatory power for extremity‐specific motor function at baseline as opposed to the unrestricted, whole‐brain MAP. On the contrary, for general motor function, the unrestricted, whole‐brain MAP yielded higher power. Finding : No associations were found for cognitive function. The extremity‐specific MAP predicted extremity‐specific motor progression over 1 and 3 years above chance level. The MAP framework allows for domain‐specific prediction of customized PD disease progression, which can inform machine learning, thereby contributing to personalized PD patient care.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neuroradiology, School of Medicine and Health, Technical University of Munich, Munich, Germany.
- Department of Neurology, University Hospital, School of Medicine, University of Regensburg, Regensburg, Germany.
- Department of Neurology, School of Medicine, University of Innsbruck, Innsbruck, Austria.
ORCID-Profile: Marlene Tahedl, Dennis M Hedderich
Förderung
- Parkinson's Progression Markers Initiative (PPMI)
Zitieren
APA
Tahedl, M., Bogdahn, U., Wimmer, B., Hedderich, D. M., Kirschke, J. S., Zimmer, C., & Wiestler, B. (2025). Domain‐Specific Prediction of Clinical Progression in Parkinson's Disease Using the Mosaic Approach. Brain and Behavior. https://doi.org/10.1002/brb3.70289
Vancouver
Tahedl M, Bogdahn U, Wimmer B, Hedderich DM, Kirschke JS, Zimmer C, et al. Domain‐Specific Prediction of Clinical Progression in Parkinson's Disease Using the Mosaic Approach. Brain and Behavior. 2025. doi:10.1002/brb3.70289
BibTeX
@article{Tahedl2025,
author = {Tahedl, Marlene and Bogdahn, Ulrich and Wimmer, Bernadette and Hedderich, Dennis M and Kirschke, Jan S and Zimmer, Claus and Wiestler, Benedikt},
title = {Domain‐Specific Prediction of Clinical Progression in Parkinson's Disease Using the Mosaic Approach},
journal = {Brain and Behavior},
year = {2025},
doi = {10.1002/brb3.70289}
}
EUVIMED